Presenter: Vivian Bykerk, Hospital for Special Surgery, New York, USA.
Saturday 15 June: 08:00–09:00 (Abstract LB0008)
This head-to-head study of abatacept versus adalimumab recruited biologic-naïve individuals with early rheumatoid arthritis, and aimed to investigate whether HLA-DRB1 alleles containing the shared epitope influence the clinical efficacy of the agents.
- News story | Early RA patients with HLA-DRB1 risk alleles may benefit from abatacept over adalimumab
- External link | Conference abstract
- External link | ClinicalTrials.gov registration page